| Next 10 |
Ad
AGIO News and Press Agios Pharmaceuticals Inc.
News | Agios Pharmaceuticals Inc. (NASDAQ:AGIO)
-
CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equity awards outside of the Company’s 2023 S...
-
2025-03-05 15:13:52 ET Emerging Biotech Firms Offer Key Insights into Growth Potential The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeu...
-
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the following conferences: Leerink...
-
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the TD Cowen 45 th Annual Healthcare Co...
-
2025-02-14 17:18:46 ET Summary Agios Pharmaceuticals' focus is on expanding Pyrukund's label to treat thalassemia and sickle cell disease, targeting multi-billion dollar markets. Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios' stock an...
-
2025-02-13 13:33:21 ET More on Agios Pharmaceuticals Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript Agios Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call Presentation Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision ...
-
2025-02-13 13:32:33 ET Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Conference Call February 13, 2025, 8:00 a.m. ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO Cecilia Jones - CFO Chris Tayl...
-
2025-02-13 06:41:10 ET More on Agios Pharmaceuticals Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision Agios Pharmaceuticals: A Long Overdue Follow Up Agios' supplemental new drug application for its thalassemia treatment gets FDA nod Agios...
-
2025-02-12 15:08:31 ET More on Agios Pharmaceuticals Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision Agios Pharmaceuticals: A Long Overdue Follow Up Agios' supplemental new drug application for its thalassemia treatment gets FDA nod Agios...
-
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, Februar...
Stock Information
Get AGIO Alerts
News, Short Squeeze, Breakout and More Instantly...
Agios Pharmaceuticals Inc. Company Name:
AGIO Stock Symbol:
NASDAQ Market:
1.1% G/L:
$31.30 Last:
1,662,508 Volume:
$32.35 Open:
$31.30 Close:
Agios Pharmaceuticals Inc. Website:
Ad
-
CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equity awards outside of the Company’s 2023 S...
-
2025-03-05 15:13:52 ET Emerging Biotech Firms Offer Key Insights into Growth Potential The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeu...
-
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the following conferences: Leerink...